<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743013</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993BA1-01</org_study_id>
    <secondary_id>2015-005198-19</secondary_id>
    <nct_id>NCT02743013</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers</brief_title>
  <official_title>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993, Administered Via the Multi-dose Reservoir NEXThaler® Dry Powder Inhaler and Via a HFA-pressurised Metered Dose Inhaler With and Without Valved Holding Chamber, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical pharmacology study is performed to evaluate the total systemic exposure and the
      lung availability of CHF 5993 DPI and pMDI with and without valved holding chamber, in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the area under the curve (AUC0-t) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Area under the curve (AUC) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>AUC 0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Maximum Plasma Concentration (Cmax) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Maximum Plasma Concentration (Cmax) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Area Under the Curve of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Area Under the Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Maximum Plasma Concentration of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Maximum Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the number of Adverse events and adverse drug reactions</measure>
    <time_frame>72 hours after adminstration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Blood pressure</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Measurement of Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the heart rate</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Measurement of Heart rate</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI (replicate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI VHC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with/without Charcoal Block with Valved Holding Chamber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 pMDI</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 DPI Test 1</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 DPI Test 2</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 pMDI replicate</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI (replicate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI VHC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject's written informed consent obtained prior to any study related procedure.

          2. Ability to understand the study procedures, the risks involved, and ability to be
             trained to use the pMDI device correctly with AIM™ (Aerosol Inhalation Monitor)
             Vitalograph®.

          3. Ability to generate sufficient PIF (at least 40 L/min) using the In-Check device
             simulating NEXThaler® device.

          4. Male and female Caucasian subjects aged 18 to 55 years inclusive.

          5. Body mass index (BMI) within the range of 18 to 30 kg/m2 inclusive.

          6. Non-smokers or ex-smokers who smoked &lt; 5 pack years (pack-years = the number of
             cigarette packs per day, times the number of years) and stopped smoking &gt; 1 year prior
             to screening.

          7. Good physical and mental status, determined on the basis of the medical history and a
             general clinical examination, at screening and before randomization.

          8. Lung function measurements within normal limits (Normal values: FEV1/FVC is &gt; 0.70 and
             FEV1 &gt; 80% predicted).

          9. Female subject of non-childbearing potential (WONCBP) defined as physiologically
             incapable of becoming pregnant (i.e. post-menopausal or permanently sterile) and
             female subjects of childbearing potential (WOCBP) fulfilling one of the following
             criteria:

               -  WOCBP with fertile male partners: they and/or their partner of childbearing
                  potential must be willing to use a double barrier contraceptive method including
                  one highly effective birth control method and one acceptable birth control method
                  (male or female condom with or without spermicide and/or cap, diaphragm or sponge
                  with spermicide), from the signature of the informed consent and until 3 months
                  after follow-up visit;

               -  WOCBP with non-fertile male partners: contraception is not required in this case.

        Exclusion Criteria:

          1. Blood donation (equal or more than 450 ml) or blood loss, less than 8 weeks prior
             screening or prior randomization.

          2. Abnormal haemoglobin level defined as &lt; 10.5 g/dl

          3. For females only: pregnant and lactating female subjects, confirmed by a positive
             serum test at screening and/or urine test before randomization.

          4. Positive HIV1 or HIV2 serology.

          5. Positive results from the Hepatitis serology which indicates acute or chronic
             Hepatitis B or Hepatitis C.

          6. Unsuitable veins for repeated venipuncture.

          7. Documented history of alcohol abuse within 12 months prior to screening.

          8. Documented history of drug abuse within 12 months prior to screening, or positive
             urine drug test performed at screening and/or before randomization.

          9. Subjects who have a positive urine test for cotinine at screening and/or before
             randomization.

         10. Clinically relevant abnormal laboratory values, suggesting an unknown disease and
             requiring further clinical investigation.

         11. Clinically relevant and uncontrolled respiratory, cardiac, hepatic, renal,
             gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may
             interfere with successful completion of this protocol.

         12. Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or
             bladder neck obstruction that in the opinion of the investigator would prevent use of
             anticholinergic.

         13. Subjects with history of asthma, including childhood asthma.

         14. Known intolerance/ hypersensitivity to any of the excipients contained in any of the
             formulations used in the trial.

         15. Abnormal 12-lead digitized Electrocardiogram (12-lead ECG) parameter (i.e.: QRS &gt; 120
             msec and/or PR &gt; 220 msec and/or HR &lt; 40 bpm and/or HR &gt; 110 bpm and/or QTcF &gt; 450 ms
             for males or QTcF &gt; 470 ms for female, considering the average from triplicate) or
             12-lead ECG evaluated as abnormal clinical significant by the investigator, at
             screening.

         16. Abnormal Blood Pressure (i.e.: Diastolic Blood Pressure &gt; 90 mmHg and/or Systolic
             Blood Pressure &gt; 140 mmHg, considering the average from triplicate) at screening.

         17. Participation in another clinical trial where investigation drug was received less
             than 8 weeks prior to screening.

         18. Subject taking any drug treatment, including prescribed or OTC medicines as well as
             vitamins, homeopathic remedies etc, in the 14 days before the screening, with the
             exception of :

               1. Occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days
                  for mild non-excluding conditions);

               2. Hormonal contraceptives;

               3. Hormonal replacement treatment for post-menopausal women.

         19. Subject taking enzyme-inducing drugs, enzyme-inhibiting drugs, biologic drugs or any
             drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide,
             nimesulide, ketoconazole) in the 3 months before screening.

         20. Heavy caffeine drinker (&gt; 5 caffeinated beverages e.g., coffee, tea, cola per day).

         21. Subject who has had a lower respiratory tract infection within 4 weeks prior to
             screening or prior randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS CPU Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

